NEW YORK, Nov. 12 - Following its broad efforts in August to contain costs, Genaissance Pharmaceuticals today said severe cuts in R&D coupled with a moderate increase revenue caused net loss to recede by more than half in the third quarter.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.
A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.
Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.